These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 29769448)

  • 1. TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25.
    Thompson EA; Ols S; Miura K; Rausch K; Narum DL; Spångberg M; Juraska M; Wille-Reece U; Weiner A; Howard RF; Long CA; Duffy PE; Johnston L; O'Neil CP; Loré K
    JCI Insight; 2018 May; 3(10):. PubMed ID: 29769448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate.
    Radtke AJ; Anderson CF; Riteau N; Rausch K; Scaria P; Kelnhofer ER; Howard RF; Sher A; Germain RN; Duffy P
    Sci Rep; 2017 Jan; 7():40312. PubMed ID: 28091576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
    Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T
    Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poor CD4
    Zaric M; Marini A; Nielsen CM; Gupta G; Mekhaiel D; Pham TP; Elias SC; Taylor IJ; de Graaf H; Payne RO; Li Y; Silk SE; Williams C; Hill AVS; Long CA; Miura K; Biswas S
    Front Immunol; 2021; 12():732667. PubMed ID: 34659219
    [No Abstract]   [Full Text] [Related]  

  • 5. Antimalarial antibody repertoire defined by plasma IG proteomics and single B cell IG sequencing.
    Coelho CH; Nadakal ST; Gonzales Hurtado P; Morrison R; Galson JD; Neal J; Wu Y; King CR; Price V; Miura K; Wong-Madden S; Alamou Doritchamou JY; Narum DL; MacDonald NJ; Snow-Smith M; Vignali M; Taylor JJ; Lefranc MP; Trück J; Long CA; Healy SA; Sagara I; Fried M; Duffy PE
    JCI Insight; 2020 Nov; 5(22):. PubMed ID: 33048842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice.
    Healy SA; Anderson C; Swihart BJ; Mwakingwe A; Gabriel EE; Decederfelt H; Hobbs CV; Rausch KM; Zhu D; Muratova O; Herrera R; Scaria PV; MacDonald NJ; Lambert LE; Zaidi I; Coelho CH; Renn JP; Wu Y; Narum DL; Duffy PE
    J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33561016
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvanting a Simian Immunodeficiency Virus Vaccine with Toll-Like Receptor Ligands Encapsulated in Nanoparticles Induces Persistent Antibody Responses and Enhanced Protection in TRIM5α Restrictive Macaques.
    Kasturi SP; Kozlowski PA; Nakaya HI; Burger MC; Russo P; Pham M; Kovalenkov Y; Silveira ELV; Havenar-Daughton C; Burton SL; Kilgore KM; Johnson MJ; Nabi R; Legere T; Sher ZJ; Chen X; Amara RR; Hunter E; Bosinger SE; Spearman P; Crotty S; Villinger F; Derdeyn CA; Wrammert J; Pulendran B
    J Virol; 2017 Feb; 91(4):. PubMed ID: 27928002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cell-traversal protein for ookinetes and sporozoites (CelTOS) formulated with potent TLR adjuvants induces high-affinity antibodies that inhibit Plasmodium falciparum infection in Anopheles stephensi.
    Pirahmadi S; Zakeri S; A Mehrizi A; D Djadid N; Raz AA; J Sani J; Abbasi R; Ghorbanzadeh Z
    Malar J; 2019 Apr; 18(1):146. PubMed ID: 31014347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies & recent development of transmission-blocking vaccines against
    Chaturvedi N; Bharti PK; Tiwari A; Singh N
    Indian J Med Res; 2016 Jun; 143(6):696-711. PubMed ID: 27748294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles.
    Kumar R; Ray PC; Datta D; Bansal GP; Angov E; Kumar N
    Vaccine; 2015 Sep; 33(39):5064-71. PubMed ID: 26299750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults.
    Chichester JA; Green BJ; Jones RM; Shoji Y; Miura K; Long CA; Lee CK; Ockenhouse CF; Morin MJ; Streatfield SJ; Yusibov V
    Vaccine; 2018 Sep; 36(39):5865-5871. PubMed ID: 30126674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a Plasmodium-Specific Carrier Protein To Enhance Production of Recombinant
    Parzych EM; Miura K; Ramanathan A; Long CA; Burns JM
    Infect Immun; 2018 Jan; 86(1):. PubMed ID: 28993460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.
    Miura K; Keister DB; Muratova OV; Sattabongkot J; Long CA; Saul A
    Malar J; 2007 Aug; 6():107. PubMed ID: 17686163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of carrier proteins to conjugate malaria transmission blocking vaccine antigens, Pfs25 and Pfs230.
    Scaria PV; Chen BB; Rowe CG; Alani N; Muratova OV; Barnafo EK; Lambert LE; Zaidi IU; Lees A; Rausch KM; Narum DL; Duffy PE
    Vaccine; 2020 Jul; 38(34):5480-5489. PubMed ID: 32600913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.
    Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S
    PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Th1 immune response to Plasmodium falciparum recombinant thrombospondin-related adhesive protein (TRAP) antigen is enhanced by TLR3-specific adjuvant, poly(I:C) in BALB/c mice.
    Mehrizi AA; Ameri Torzani M; Zakeri S; Jafary Zadeh A; Babaeekhou L
    Parasite Immunol; 2018 Jul; 40(7):e12538. PubMed ID: 29799636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New adenovirus-based vaccine vectors targeting Pfs25 elicit antibodies that inhibit Plasmodium falciparum transmission.
    McGuire KA; Miura K; Wiethoff CM; Williamson KC
    Malar J; 2017 Jun; 16(1):254. PubMed ID: 28619071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accelerated and long term stability study of Pfs25-EPA conjugates adjuvanted with Alhydrogel®.
    Zhu D; Wu Y; McClellan H; Dai W; Rausch K; Jones D; Aebig J; Barnafo E; Butler B; Lambert L; Narum DL; Duffy PE
    Vaccine; 2017 May; 35(24):3232-3238. PubMed ID: 28479180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative functional potency of DNA vaccines encoding Plasmodium falciparum transmission blocking target antigens Pfs48/45 and Pfs25 administered alone or in combination by in vivo electroporation in rhesus macaques.
    Datta D; Bansal GP; Grasperge B; Martin DS; Philipp M; Gerloff D; Ellefsen B; Hannaman D; Kumar N
    Vaccine; 2017 Dec; 35(50):7049-7056. PubMed ID: 29132995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of dimorphic and C-terminal fragments of Plasmodium falciparum MSP2 formulated with different adjuvants in mice.
    Balam S; Jafarshad A; Servis C; Frank G; Reed S; Pink R; Druilhe P; Spertini F; Corradin G
    Vaccine; 2016 Mar; 34(13):1566-1574. PubMed ID: 26874325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.